{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-22-000065","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.184229+00:00","generated_at":"2026-06-22T04:57:08.787516+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Landec shareholders approve amendment to 2019 Stock Incentive Plan increasing share reserve by 759,797 shares","bullets":["Shareholders elected Katrina L. Houde, Nelson Obus, and Jeffrey L. Edwards to the board with votes ranging from 15.2M to 17.7M for each.","Amendment increases share reserve from 2,000,000 to 2,759,797 shares (759,797 new shares) and increases ISO limit to same total.","Non-employee director annual award limit increased from $120,000 to $350,000 per fiscal year.","Ratified Ernst & Young as independent auditor for fiscal year ending May 28, 2023 with 24.2M for, 9k against.","Advisory vote on named executive officer compensation approved: 20.2M for, 1.1M against, 324k abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-22-000065","json":"https://secwatch.observer/filing/0001005286-22-000065.json","markdown":"https://secwatch.observer/filing/0001005286-22-000065.md","text":"https://secwatch.observer/filing/0001005286-22-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/lndc-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:57:08.787516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b8f84d32f5c79f3c1cd0283b253683e83799985","claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of amendment to the Landec Corporation 2019 Stock Incentive Plan.","evidence_excerpt":"Stockholders approved the amendment to the Landec Corporation 2019 Stock Incentive Plan, with votes as follows: For Against Abstain Broker Non-Votes 18,487,481 3,096,263 16,615 2,698,258","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"4fdf9071a291519893100a8c308ddc9a8b8de0d2","claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Approval of non-binding advisory proposal on the executive compensation of the Company's named executive officers.","evidence_excerpt":"Stockholders approved the compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes as follows: For Against Abstain Broker Non-Votes 20,189,411 1,086,858 324,090 2,698,258","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"7fa2df393679d0cb12bad053f89f633327b93285","claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Election of three directors for a two-year term.","evidence_excerpt":"The voting results for the election of directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Katrina L. Houde 15,180,997 6,419,362 2,698,258 Nelson Obus 17,689,049 3,911,310 2,698,258 Jeffrey L. Edwards 17,743,088 3,857,271 2,698,258","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9219ef775f1b96ae5298aa11ce4d832c830c093e","claim":"LIFECORE BIOMEDICAL, INC. DE shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023 at the 2023-05-28 meeting.","evidence_excerpt":"Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending May 28, 2023, with votes as follows: For Against Abstain 24,245,636 8,975 44,006","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528622000065/0001005286-22-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}